Skip to content

13F-HR filed by Pivotal bioVenture Partners Investment Advisor LLC

Pivotal bioVenture Partners Investment Advisor LLC filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-02-13, with 10 holding rows worth $229,952,126.

Accession
0001012975-23-000082
Filed
2023-02-13
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2022

A holdings report, 10 entries on the cover page, a total value of $229,952,126 stated on the cover page (in dollars after the unit check, H1), rows summing to $229,952,126 with VALUE read as dollars as filed, 13F file number 028-20630. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
KARUNA THERAPEUTICS INC48576A100COM765,895$150,498,368dollars as filed
VAXCYTE INC COM92243G108Stock693,039$33,231,220dollars as filed
RALLYBIO CORP75120L100COM2,404,644$15,798,511dollars as filed
ARCUTIS BIOTHERAPEUTICS INC03969K108COM569,041$8,421,807dollars as filed
VIGIL NEUROSCIENCE INC92673K108COM560,595$7,007,438dollars as filed
FUSION PHARMACEUTICALS INC36118A100COM1,560,984$4,917,100dollars as filed
EXSCIENTIA PLC30223G102ADS772,285$4,116,279dollars as filed
INOZYME PHARMA INC45790W108COM2,661,154$2,794,212dollars as filed
BOLT BIOTHERAPEUTICS INC097702104COM1,891,467$2,458,907dollars as filed
ALIGOS THERAPEUTICS INC COM NEW01626L105Stock743,215$708,284dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001012975-23-000082this filing2023-02-13acceptance time not in the bulk data set